Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.

Abstract

With the reporting of five studies with different and complementary designs, but all demonstrating a similar and striking benefit from the targeted drug trastuzumab in HER2-overexpressing breast cancer, the year 2005 has profoundly marked the history of randomised adjuvant breast cancer trials. In view of the halving in recurrence risk, obtained at the real but small risk of cardiotoxicity, these results are generating hope in women affected with this aggressive form of the disease. But at the same time these results pose real challenges to healthcare authorities faced with the high cost of the anti-HER2 monoclonal antibody. These results also leave oncologists and patients to deal with a complex treatment tailoring process that needs to take into account risk of an early relapse as well as the benefit versus risk of trastuzumab according to the different patterns of administration used in the clinical trials.

Statistics

050010001500'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

1,618 Citations

Semantic Scholar estimates that this publication has 1,618 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{PiccartGebhart2006AdjuvantTT, title={Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.}, author={Martine J. Piccart-Gebhart}, journal={European journal of cancer}, year={2006}, volume={42 12}, pages={1715-9} }